
    
      A study to evaluate the safety and effect of treatment with experimental antiviral drugs in
      combination with ribavirin in treatment-na√Øve participants with genotype 4 hepatitis C
      infection. The study will test the safety and effects of this alternative treatment for up to
      12 weeks. Secondary objectives of this study are to determine the pharmacokinetics of the
      study drugs when co-administered, and to evaluate HCV RNA kinetics during treatment.
    
  